684P - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT)

H Riess,J Braverman,M Reni,A.C Dueck,A Hendifar,D.-Y Oh,C.-P Li,T Macarulla Mercade,A Shah,N Joshi,M Botterman,E Mantovani,B Lu,M.A Tempero

doi:10.1093/annonc/mdz247.012

684P - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT)

H Riess, J Braverman + Show 12 more

Open Access

https://doi.org/10.1093/annonc/mdz247.012

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 1	License type: publisher-specific-oa

Affiliation: Pharmerit (United States), Taipei Veterans General Hospital, San Raffaele University of Rome, Vall d'Hebron Institute of Oncology, Cedars-Sinai Medical Center, Seoul National University Hospital, Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Freie Universität Berlin

#End Of Treatment #Part-time Employment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

684P - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT)

Full Text